Spero Therapeutics (SPRO) Non-Current Assets (2016 - 2026)

Spero Therapeutics (SPRO) has reported Non-Current Assets for 11 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 56.5% year-over-year to $1.2 million; the trailing twelve-month figure through Jun 2026 stood at $6.1 million (down 51.48% YoY), and the FY2025 full-year result was $1.6 million, down 50.02% from the prior year.
• Non-Current Assets slipped to $1.2 million in Q2 2026 per SPRO's latest filing, from $1.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $51.2 million in Q4 2023 and bottomed at $1.2 million in Q2 2026.
• Historically, Non-Current Assets has averaged $11.0 million across 5 years, with a median of $7.7 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 355.68% in 2023, then plunged 93.62% in 2024.
• Over 5 years, Non-Current Assets stood at $11.2 million in 2022, then jumped by 355.68% to $51.2 million in 2023, then slumped by 93.62% to $3.3 million in 2024, then tumbled by 50.02% to $1.6 million in 2025, then declined by 27.62% to $1.2 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $1.2 million, $1.4 million, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.